PharmaTimesNews & Politicsnews

Mission Therapeutics divests MTX652 to Dimerix in deal worth up to $292 million

Wednesday, July 22, 2026John PinchingView original

Move sharpens Mission’s focus on CNS pipeline as renal specialist takes AKI asset forward

Read the full article on the original site.